Karyopharm Therapeutics Inc.
KPTI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $38 | $39 | $39 | $62 |
| Short-Term Investments | $8 | $13 | $31 | $46 |
| Receivables | $32 | $33 | $35 | $31 |
| Inventory | $4 | $5 | $5 | $5 |
| Other Curr. Assets | $8 | $8 | $10 | $12 |
| Total Curr. Assets | $90 | $98 | $120 | $156 |
| Property Plant & Equip (Net) | $5 | $5 | $6 | $6 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $2 | $2 | $2 |
| Total NC Assets | $6 | $7 | $7 | $8 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $96 | $105 | $128 | $164 |
| Liabilities | – | – | – | – |
| Payables | $5 | $3 | $6 | $5 |
| Short-Term Debt | $14 | $32 | $25 | $25 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $68 | $65 | $59 | $62 |
| Total Curr. Liab. | $87 | $99 | $90 | $92 |
| LT Debt | $183 | $159 | $161 | $170 |
| Deferred Rev, NC | $73 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $22 | $86 | $82 | $89 |
| Total NC Liab. | $278 | $245 | $243 | $258 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $6 | $8 | $7 | $7 |
| Total Liabilities | $365 | $344 | $334 | $350 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,657 | -$1,624 | -$1,587 | -$1,563 |
| AOCI | -$0 | -$0 | -$0 | -$0 |
| Other Equity | $1,388 | $1,385 | $1,381 | $1,378 |
| Total Equity | -$269 | -$239 | -$206 | -$186 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $96 | $105 | $128 | $164 |
| Net Debt | $159 | $152 | $148 | $132 |